WSJ's blog on health and the business of health.

Visit WSJ.com: Health Blog

P&G Drops Nastech Osteoporosis Project

Posted on November 07, 2007

Proctor & Gamble sneezed and Nastech Pharmaceutical caught cold.The consumer-products giant pulled out of its partnership with Nastech to develop a nasal spray for osteoporosis, and Nastech stock was down $5.30, or 38%, to $8.69 in afternoon trading. The companies had aimed to bring the nasal form of teriparatide to market as soon as next year, around the time target Merck s popular osteoporosis pill Fosamax is coming off patent. At this point in time, I think that timing is no longer available, clearly, and I think that may have been one of the reasons, or the major reason, for P&G s d...

Original article link


actonel , fosamax , obesity , osteoporosis